GPP
RLMD icon

Great Point Partners’s Relmada Therapeutics RLMD Stock Holding History

Great Point Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.86M Buy
+842,106
New +$3.98M 1.35% 28
2022
Q4 		– Sell
-510,000
Closed -$18.9M – 52
2022
Q3 		$18.9M Sell
510,000
-190,000
-27% -$5.26M 4.55% 9
2022
Q2 		$13.3M Sell
700,000
-90,000
-11% -$1.96M 3.19% 13
2022
Q1 		$21.3M Buy
790,000
+72,680
+10% +$1.5M 5.15% 11
2021
Q4 		$16.2M Buy
+717,320
New +$16M 3.59% 9

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Great Point Partners's RLMD Position: Q1 2026 in Review

Great Point Partners opened a new position in Relmada Therapeutics (RLMD) in Q1 2026: 842,106 shares worth $5.86M. The stake represents 1.35% of the portfolio and ranks #28 among its holdings. This is a return to the name: Great Point Partners previously reported a position in RLMD as recently as Q3 2022.

Great Point Partners first reported a position in RLMD in Q4 2021 and has held it in 5 quarters since. The position peaked at $21.3M in Q1 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Great Point Partners held 842,106 shares of Relmada Therapeutics worth $5.86M as of Q1 2026.
  • Relmada Therapeutics was a new Great Point Partners position in Q1 2026.
  • Relmada Therapeutics made up 1.35% of Great Point Partners's portfolio in Q1 2026, its #28 holding.
  • Great Point Partners first reported a position in Relmada Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • Great Point Partners's Relmada Therapeutics position peaked at $21.3M in Q1 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.